Review on gene and cell therapies in prostate cancer treatment: prospects and challenges

Abstract

Gene and cell therapies have emerged as innovative therapeutic strategies, offering a new paradigm in the treatment of prostate cancer. This review explores the current state of gene and cell therapies, including their mechanisms, applications, and the challenges faced in clinical translation. The article selection was based on the 2020 preferred reporting items for systematic reviews and meta-analyses (PRISMA). Eighty-four (84) articles (published in English between 2018 and 2024) from standard electronic databases were extracted and reviewed. Key therapeutic approaches such as viral vector-mediated delivery, CRISPR-Cas9 gene editing, suicide genes, cell-based therapies like CAR T cell therapy, and dendritic cell vaccines that target specific tumor antigens were reviewed. These therapies promise to enhance therapeutic efficacy with few challenges, like off-target effects, limited delivery efficiency, and immune-related toxicities associated with delivery. Advances in CAR T cells, nanoparticle-based gene delivery systems, and epigenetic modulation are potential solutions to these challenges. Combination therapies involving gene and cell therapies with immunotherapies and oncolytic viruses hold the potential for synergistic treatment effects. Certain critical regulatory, ethical, and accessibility issues must be addressed to ensure the safe and equitable deployment of these therapies. Continued research and innovation in gene and cell therapies and streamlined regulatory pathways will be crucial for realizing their full potential in treating prostate cancer. Overcoming these challenges and fears confronting gene and cell therapies worldwide might facilitate a stream of personalized medicine in prostate oncology.

Keywords

CAR-T / CRISPR-Cas9 / vector-mediated / gene therapy

References

[1] Key statistics for prostate cancer. 2024. Available from: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html [Last accessed on 20 Mar 2025]

[2] Rawla P.Epidemiology of prostate cancer.World J Oncol2019;10:63-89 PMCID:PMC6497009

[3] Wang Y,You Z.Comparative analysis of the incidence, diagnosis and treatment of prostate cancer between China and the United States.Serican J Med2025;2

[4] Prostate Cancer Foundation. 2022. Available from: https://www.pcf.org [Last accessed on 20 Mar 2025]

[5] Chen T,Chen Y.Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.Cancer Cell Int2024;24:133 PMCID:PMC11017638

[6] Stefanoudakis D,Sun AW.The potential revolution of cancer treatment with CRISPR technology.Cancers2023;15:1813 PMCID:PMC10046289

[7] Li YR,Yang L.Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.J Biomed Sci2024;31:5 PMCID:PMC10785504

[8] Logotheti S,Zolota V.Lineage plasticity and stemness phenotypes in prostate cancer: harnessing the power of integrated “omics” approaches to explore measurable metrics.Cancers2023;15:4357 PMCID:PMC10486655

[9] Chen L,Wang Y,Ma X.Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer.Oncotarget2017;8:79854-63 PMCID:PMC5668100

[10] Desai K,Sharifi N.Hormonal therapy for prostate cancer.Endocr Rev2021;42:354-73 PMCID:PMC8152444

[11] Corn PG,Zurita A.Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol2019;20:1432-43 PMCID:PMC6858999

[12] Michaelson MD,Gargollo PC,Dahl DM.Management of complications of prostate cancer treatment.CA Cancer J Clin2008;58:196-213 PMCID:PMC2900775

[13] Talkar SS.Gene therapy for prostate cancer: a review.Endocr Metab Immune Disord Drug Targets2021;21:385-96

[14] Gudenkauf LM,Gonzalez BD,Autio K.Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management.Am Soc Clin Oncol Educ Book2024;44:e433126

[15] Dogbey DM,Fajemisin E.Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy.Drug Deliv Transl Res2023;13:2719-38 PMCID:PMC10257536

[16] Eade TN,Horwitz EM,Hanks GE.What dose of external-beam radiation is high enough for prostate cancer?.Int J Radiat Oncol Biol Phys2007;68:682-9 PMCID:PMC2770596

[17] Osuchowski M,Latos W.The use of upconversion nanoparticles in prostate cancer photodynamic therapy.Life2021;11:360 PMCID:PMC8073589

[18] Runcie KD.Prostate Cancer immunotherapy-finally in from the cold?.Curr Oncol Rep2021;23:88

[19] Kanu GA,Abu Odeh RO.Gold nanoparticle-mediated gene therapy.Cancers2022;14:5366 PMCID:PMC9653658

[20] Allami P,Rezaei N.The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma.Front Mol Biosci2022;9:1083645 PMCID:PMC9846545

[21] Beach MA,Gao Y.Polymeric nanoparticles for drug delivery.Chem Rev2024;124:5505-616 PMCID:PMC11086401

[22] Bajpai S,Sonker M.Recent advances in nanoparticle-based cancer treatment: a review.ACS Appl Nano Mater2021;4:6441-70

[23] Lee NH,Taghizadeh A,Kim HS.Cell membrane-cloaked nanotherapeutics for targeted drug delivery.Int J Mol Sci2022;23:2223 PMCID:PMC8879543

[24] Kadry MO.CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.Plos One2024;19:e0302264 PMCID:PMC11081254

[25] Zhang H,An C.Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.Mol Cancer2021;20:126 PMCID:PMC8484294

[26] Tabibian M,Motevaseli E.Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.Cell Commun Signal2024;22:504 PMCID:PMC11484332

[27] Kumari S,Tiwari R,Subudhi BB.Therapeutic potential of p53 reactivation in prostate cancer: strategies and opportunities.Eur J Pharmacol2022;919:174807

[28] Belete TM.The current status of gene therapy for the treatment of cancer.Biol Targets Ther2021;2021:67-77 PMCID:PMC7987258

[29] Altanerova U,Benejova K.Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.Int J Cancer2021;148:128-39

[30] Yanagisawa N,Tabata KI.Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer.Asian J Urol2021;8:280-8 PMCID:PMC8356062

[31] Dhankhar R,Mohanty A.Microbial enzymes used in prodrug activation for cancer therapy: insights and future perspectives.Curr Protein Pept Sci2021;22:514-25

[32] Mani R,Balu KE.A novel protozoa parasite-derived protein adjuvant is effective in immunization with cancer cells to activate the cancer-specific protective immunity and inhibit the cancer growth in a murine model of colorectal cancer.Cells2024;13:111 PMCID:PMC10814441

[33] Li J,Li L,Dong M.Biomembrane-wrapped gene delivery nanoparticles for cancer therapy.Front Bioeng Biotechnol2023;11:1211753 PMCID:PMC10282192

[34] Wang I,Wang BY,Uchio E.Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy.Am J Clin Exp Urol2022;10:210-33 PMCID:PMC9428569

[35] Wang F,Feng X.Advances in PSMA-targeted therapy for prostate cancer.Prostate Cancer Prostatic Dis2022;25:11-26

[36] Flugel CL,Krenciute G.Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.Nat Rev Clin Oncol2023;20:49-62 PMCID:PMC10278599

[37] Escudero-Lourdes C,Tokar EJ.Stem cells as target for prostate cancer therapy: opportunities and challenges.Stem Cell Rev Rep2022;18:2833-51 PMCID:PMC9716656

[38] Hafron JM,Ferro C,Flanders SC.Real-world effectiveness of sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents.Adv Ther2022;39:2515-32 PMCID:PMC9123060

[39] Zanotta S,De Filippi R.Enhancing dendritic cell cancer vaccination: the synergy of immune checkpoint inhibitors in combined therapies.Int J Mol Sci2024;25:7509 PMCID:PMC11277144

[40] Perera Molligoda Arachchige AS.Human NK cells: from development to effector functions.Innate Immun2021;27:212-29 PMCID:PMC8054151

[41] Gong Y,Wang J.Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.J Hematol Oncol2021;14:73 PMCID:PMC8088725

[42] Bou-Dargham MJ,Sang QA.Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.BMC Cancer2020;20:572 PMCID:PMC7302357

[43] Liu LL,Harmenberg U.Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.J Immunother Cancer2023;11:e005841 PMCID:PMC9990684

[44] Hong B,Prabhu VV,El-Deiry WS.Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities.Curr Drug Targets2014;15:80-9

[45] Han HA,Soh BS.Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing.J Mol Med2020;98:615-32 PMCID:PMC7220873

[46] Shimabukuro-Vornhagen A,Subklewe M.Cytokine release syndrome.J Immunother Cancer2018;6:56 PMCID:PMC6003181

[47] Kim TJ.Current status and future perspectives of checkpoint inhibitor immunotherapy for prostate cancer: a comprehensive review.Int J Mol Sci2020;21:5484 PMCID:PMC7432105

[48] Freyer CW.Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.J Allergy Clin Immunol2020;146:940-8

[49] Abou-el-Enein M,Feldman SA.Scalable manufacturing of CAR T cells for cancer immunotherapy.Blood Cancer Dis2021;2:408-22 PMCID:PMC8462122

[50] Townsend BA.Human genome editing: how to prevent rogue actors.BMC Med Ethics2020;21:95 PMCID:PMC7541231

[51] Pipe SW,Chowdary P.Gene therapy: practical aspects of implementation.Haemophilia2022;28 Suppl 4:44-52 PMCID:PMC9324089

[52] Zu H.Non-viral vectors in gene therapy: recent development, challenges, and prospects.AAPS J2021;23:78 PMCID:PMC8171234

[53] Weimin S,Qianghong D.Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.Cancer Biol Ther2020;21:570-80 PMCID:PMC7515537

[54] Fisher R,Swanton C.Cancer heterogeneity: implications for targeted therapeutics.Br J Cancer2013;108:479-85 PMCID:PMC3593543

[55] Narayan V,Jung IY.PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.Nat Med2022;28:724-34

[56] Quinn C,Thomas J.MIT NEWDIGS FoCUS Writing GroupEstimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system.Value Health2019;22:621-6

[57] Rubanyi GM.The future of human gene therapy.Mol Asp Med2001;22:113-42

[58] Porter LH,Risbridger GP,Taylor RA.Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies.J Steroid Biochem Mol Biol2024;243:106571

[59] Ohomoimen G, Oboma YI, Beredugo S, Beredugo L. MutS homolog 2 and MutS homolog 3 genes are equivocal in prostate disease diagnosis: a study from Niger Delta University Teaching Hospital (NDUTH) in Okolobiri, Bayelsa State, Nigeria.Acad J Health Sci2024;39:23

[60] Patra D.Polymer-based nanoparticles as efficient non-viral vectors for gene delivery in CAR-T cell therapy.Exon2024;1:87-96

[61] Patnaik S.Drugs targeting epigenetic modifications and plausible therapeutic strategies against colorectal cancer.Front Pharmacol2019;10:588 PMCID:PMC6563763

[62] Shalhout SZ,Emerick KS.Therapy with oncolytic viruses: progress and challenges.Nat Rev Clin Oncol2023;20:160-77

[63] Liu Y,Huang R.Strategies to enhance CAR-T persistence.Biomark Res2022;10:86 PMCID:PMC9685914